Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAge Labs, Inc.BIOA · Entity 5569 | Director | June 10, 2026 | June 12, 2026 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 10, 2022 | January 12, 2022 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director · Chief Executive Officer | September 14, 2026 | September 15, 2026 |
| Silence Therapeutics plcSLN · Entity 5028 | Director | January 02, 2025 | January 06, 2025 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | January 09, 2026 | January 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAge Labs, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 · Expires 2036-06-09 | Direct | 22,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 22,000 · Balance 22,000 F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
LISATA THERAPEUTICS, INC.
Report date January 10, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 209,753 |
Reported balance
After 2022-01-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-10 · Grant · Acquired 65,430 · Balance 209,753 F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2: Includes 137,207 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023.
F2: Includes 137,207 unvested restricted stock units.
NewAmsterdam Pharma Co N.V.
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 792,923 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Purchase · Acquired 10,000 · Balance 792,923 F1: Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting. F2: Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 285,715 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 285,715 F3: These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
F2: Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.
F3: These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT.
Silence Therapeutics plc
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2035-01-02 | Direct | 48,000 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 48,000 · Balance 48,000 F1: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date.
TENAX THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 30,000 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 80,000 |
| Common StockSEC Table I · non-derivative | Direct | 2,881 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,881 |
| Pre-Funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | Direct | 47,500 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 47,500 F1: The pre-funded warrant has no expiration date. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 25,000 F2: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The pre-funded warrant has no expiration date.
F2: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 15, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | PurchaseOrdinary Shares | 10,000 | $22.65 | $226,500.00 |
DisclosureSEC source: 0001193125-26-391985 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,923 F1 · balance_after: Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting. F2 · balance_after: Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:31 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0001573785-26-000003 · form4-06122026_080647.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:08 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 443,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085947 · ownership.xml · derivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,267 Underlying: Ordinary Shares · 443,707 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F2 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:08 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 443,707 | $33.25 | $14,753,257.75 |
DisclosureSEC source: 0001193125-26-085947 · ownership.xml · nonDerivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,144 Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:08 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 443,707 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085947 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 183,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · derivative · entry 14 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 682,974 Underlying: Ordinary Shares · 183,332 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F10 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 17,924 | $34.44 | $617,302.56 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 10 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,144 F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F9 · balance_after: The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 165,408 | $33.63 | $5,562,671.04 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 9 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,783 F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 183,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 8 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 643,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 58,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · derivative · entry 13 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 866,306 Underlying: Ordinary Shares · 58,253 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F10 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 1,300 | $36.68 | $47,684.00 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 7 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,859 F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 10,436 | $35.96 | $375,278.56 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 6 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,159 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 46,517 | $35.11 | $1,633,211.87 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 5 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,595 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 58,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 4 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 518,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 64,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · derivative · entry 12 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 924,559 Underlying: Ordinary Shares · 64,708 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F10 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 3,161 | $36.46 | $115,250.06 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,859 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 61,547 | $36.13 | $2,223,693.11 |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,020 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 64,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 524,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:49 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001573785-26-000001 · primary_doc.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-01-09 Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:34 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 364,000 | $0.00 Strike: $35.45 | $0.00 |
DisclosureSEC source: 0001193125-26-009272 · ownership.xml · derivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 364,000 Underlying: Ordinary Shares · 364,000 shares Expires 2036-01-07 F5 · derivative.exercise_date: 25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:34 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 81,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-009272 · ownership.xml · nonDerivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,859 F3 · shares: Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F4 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:34 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 11,582 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-009272 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,859 F1 · kind: Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 12:13 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001654954-25-007738 · section16.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-07-01 Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:42 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001415889-25-016283 · form4-06092025_080644.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionRestricted Stock Unit · Derivative | 38,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046934 · ownership.xml · derivative · entry 5 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 38,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F6 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F5 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F5 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantRestricted Stock Unit · Derivative | 38,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046934 · ownership.xml · derivative · entry 4 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,394 Underlying: Ordinary Shares · 38,394 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F6 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F5 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F5 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 12,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,441 F2 · shares: Ordinary shares sold to satisfy tax withholding obligation arising upon the vesting of restricted stock units ("RSUs"). F3 · price: These shares were sold in multiple transactions at a price ranging from $22.88 to $23.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 38,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 30,992 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,305 F1 · shares: Reflects ordinary shares issued to the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout shares became fixed and irrevocable on the Closing Date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:21 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 123,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-003022 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,529 F1 · shares: Represenets restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:21 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 670,467 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-25-003022 · ownership.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,467 Underlying: Ordinary Shares · 670,467 shares Expires 2035-01-06 F3 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantShare Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-000749 · form4-01062025_040115.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 00:54 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001654954-24-015472 · section16.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-10 Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 21:01 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GiftWarrant (right to buy) · Derivative | 15,000 | $11.50 Strike: $11.50 | $172,500.00 |
DisclosureSEC source: 0000950170-24-114388 · ownership.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 15,000 shares Expires 2027-11-23 Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024042 · form4-09272024_080914.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-09-24 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | PurchaseOrdinary Shares | 5,000 | $16.27 | $81,350.00 |
DisclosureSEC source: 0000950170-24-099871 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,784 Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 23:42 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseWarrant · Derivative | 25,000 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001654954-24-010192 · section16.xml · derivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · price: . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. F4 · derivative.expiration_date: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029. Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 23:42 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchasePre-Funded Warrant · Derivative | 47,500 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001654954-24-010192 · section16.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires not disclosed F1 · price: . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. F3 · derivative.expiration_date: The pre-funded warrant has no expiration date. Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 23:42 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-24-010192 · section16.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,881 F1 · price: . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. F2 · balance_after: The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 12:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | PurchaseOrdinary Shares | 5,000 | $17.26 | $86,308.50 |
DisclosureSEC source: 0000950170-24-076468 · ownership.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,784 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.115 to $17.60, inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, specific trade amounts and pricing within the range set forth in this footnote at which the transaction was effected. Read SEC document |
| March 26, 2024 Filed Sep 27, 2024 20:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 33,986 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001415889-24-024042 · form4-09272024_080914.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,986 Underlying: Common Stock · 33,986 shares Expires 2034-03-25 F2 · date: This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). F3 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 26, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 1,039,939 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0000950170-24-001116 · ownership.xml · derivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,039,939 Underlying: Ordinary Shares · 1,039,939 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 00:45 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001654954-22-008234 · section16.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-09 Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:09 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001573785-22-000002 · wf-form4_164202172785612.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,753 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 137,207 unvested restricted stock units. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionSeries B Preferred Stock · Derivative | 512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-006926 · section16.xml · derivative · entry 3 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 512,000 shares Expires 2021-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. F2 · derivative.exercise_price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. F2 · price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantCommon Stock | 512,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-006926 · section16.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,645 F1 · security: On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. F2 · price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001654954-21-006926 · section16.xml · derivative · entry 2 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2031-06-10 Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:16 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001573785-21-000005 · wf-form4_161049336019219.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,323 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 88,798 unvested restricted stock units. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:01 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | PurchaseCommon Stock | 55,525 | $1.80 | $99,945.00 |
DisclosureSEC source: 0001573785-20-000017 · wf-form4_159976808251973.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,588 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transaction prices ranging from $1.74 to $1.84, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes 51,063 shares of unvested restricted stock units. Read SEC document |
| July 28, 2020 Filed Aug 12, 2020 13:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 51,063 | $2.35 | $119,998.05 |
DisclosureSEC source: 0001573785-20-000014 · wf-form4_159723846932411.xml · nonDerivative · entry 1 Davidson Michael H. · CIK 0001573785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,063 F1 · shares: Represents 51,063 shares of restricted stock units granted under the 2018 Equity Incentive Compensation Plan. The shares of restricted stock units will vest in annual installments over a three-year period with the initial vesting on July 28, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.